secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2026-08-12T20:15:20+00:00
Accession:  0001493152-26-037360
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q2 2026: revenue $9.1M, income $0.3M vs prior loss; thyroid revenue +9% YoY
--------------------------------------------------------------------------------

- Q2 revenue $9.1M, up 9% Pro Forma (ex-PancraGEN); income from continuing ops $0.3M vs $0.5M loss prior year.
- Thyroid revenue +9% YoY, volume +6%; TTM thyroid revenue $36.1M, up 11%; gross margin 62% vs 54% Pro Forma.
- Adjusted EBITDA $0.7M (8% margin) vs $0.2M Pro Forma prior year; includes $0.2M one-time strategic fees.
- H1 2026 income $1.1M vs $0.2M loss Pro Forma; Adjusted EBITDA $2.3M (13% margin); debt-free balance sheet.
- Adding Chief Scientific Officer Sept 8, 2026; pancreatic cancer program in development, no revenue expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226037360/0001493152-26-037360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226037360/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer